Articles from BlossomHill Therapeutics, Inc.

BH-30643, a first-in-class, macrocyclic OMNI-EGFR™ inhibitor, demonstrates preliminary anti-tumor activity across a variety of advanced EGFR-mutant non-small cell lung cancers with complex and difficult-to-treat resistance mutations

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced that preliminary findings from the dose escalation portion of the company’s ongoing, first-in-human Phase 1/2 SOLARA trial of BH-30643, will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held from October 22 - 26, 2025, in Boston, MA.

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the first patient dosed in the expansion cohorts of the SOLARA trial (NCT06706076), the first-in-human trial of BH-30643, a first-in-class, macrocyclic, non-covalent, mutant selective OMNI-EGFRTM inhibitor having sub-nanomolar potency against classical and atypical EGFR mutations that is maintained even in the presence of T790M +/- C797S resistance mutations.

Jason Keyes is a veteran corporate executive within the biopharmaceutical industry who brings a breadth of leadership experience in the areas of finance, strategic planning and business development

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, announced that an abstract describing the design and discovery of the company’s novel, macrocyclic, reversible, mutant-selective OMNI-EGFR™ inhibitor, BH-30643, was accepted for a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL on April 29, 2025.

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the first cohort of patients has been dosed in the SOLARA study (NCT06706076). SOLARA is a global, open label, dose escalation and expansion Phase 1/2 clinical trial assessing the safety, efficacy and tolerability of BH-30643 for locally advanced or metastatic non-small cell lung cancer (NSCLC) bearing EGFR or HER2 mutations.

BlossomHill Therapeutics, Inc., a clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the appointment of Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President. Dr. Oxnard is a globally recognized clinical and translational cancer investigator who spent nearly 10 years on faculty at the Dana-Farber Cancer Institute and Harvard Medical School. His research catalyzed many of the early clinical insights into sensitivity and resistance to EGFR inhibitors in advanced lung cancer, including the first description of the EGFR C797S resistance mutation, reported in Nature Medicine in 2015.

BlossomHill Therapeutics, a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE). The prestigious honor recognizes Dr. Cui’s direct role in the innovation of new medicines to fight cancer and address urgent medical needs.